Cheri E. Klein

1.2k total citations
34 papers, 930 citations indexed

About

Cheri E. Klein is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Emergency Medicine. According to data from OpenAlex, Cheri E. Klein has authored 34 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Emergency Medicine. Recurrent topics in Cheri E. Klein's work include HIV/AIDS drug development and treatment (12 papers), Endometriosis Research and Treatment (6 papers) and HIV-related health complications and treatments (6 papers). Cheri E. Klein is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), Endometriosis Research and Treatment (6 papers) and HIV-related health complications and treatments (6 papers). Cheri E. Klein collaborates with scholars based in United States, United Kingdom and Egypt. Cheri E. Klein's co-authors include Juki Ng, Walid M. Awni, Yi‐Lin Chiu, Kristof Chwalisż, George J. Hanna, Kristine B. Patterson, Naser L. Rezk, Michael Blake, Joseph J. Eron and Rosa F. Yeh and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Cheri E. Klein

33 papers receiving 901 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cheri E. Klein United States	16	293	172	169	139	135	34	930
Jérôme Dimet France	16	153 0.5×	214 1.2×	76 0.4×	105 0.8×	134 1.0×	47	1.0k
Alessandra Manca Italy	19	377 1.3×	51 0.3×	150 0.9×	45 0.3×	48 0.4×	98	1.5k
Cynthia Behling United States	17	135 0.5×	9 0.1×	52 0.3×	119 0.9×	68 0.5×	27	2.2k
Karl Brendel France	11	168 0.6×	19 0.1×	171 1.0×	291 2.1×	6 0.0×	19	1.1k
Daniel D. Bankson United States	18	71 0.2×	12 0.1×	33 0.2×	75 0.5×	70 0.5×	41	895
Joseph M. Custodio United States	18	1.4k 4.6×	19 0.1×	232 1.4×	207 1.5×	13 0.1×	40	2.0k
Monika Sarkar United States	19	20 0.1×	95 0.6×	37 0.2×	114 0.8×	157 1.2×	63	1.2k
Thomas Demant Germany	21	390 1.3×	35 0.2×	42 0.2×	18 0.1×	15 0.1×	41	1.9k
Julie Borland United States	26	1.3k 4.3×	10 0.1×	154 0.9×	304 2.2×	12 0.1×	52	2.0k
Neil Buss Switzerland	13	375 1.3×	7 0.0×	61 0.4×	90 0.6×	8 0.1×	17	655

Countries citing papers authored by Cheri E. Klein

Since Specialization

Citations

This map shows the geographic impact of Cheri E. Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheri E. Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheri E. Klein more than expected).

Fields of papers citing papers by Cheri E. Klein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheri E. Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheri E. Klein. The network helps show where Cheri E. Klein may publish in the future.

Co-authorship network of co-authors of Cheri E. Klein

This figure shows the co-authorship network connecting the top 25 collaborators of Cheri E. Klein. A scholar is included among the top collaborators of Cheri E. Klein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheri E. Klein. Cheri E. Klein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kikuchi, R., Yuli Qian, Mohamed Badawi, et al.. (2024). Coproporphyrin‐I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug–Drug Interactions: Cedirogant Case Study. Clinical Pharmacology & Therapeutics. 116(5). 1334–1342. 4 indexed citations

Alami, Negar Niki, David C. Carter, Nisha V. Kwatra, et al.. (2023). A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity. PLoS neglected tropical diseases. 17(7). e0011392–e0011392. 3 indexed citations

Shebley, Mohamad, Akshanth R. Polepally, Ahmed Nader, et al.. (2019). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical Pharmacokinetics. 59(3). 297–309. 45 indexed citations

Goss, Sandra, Cheri E. Klein, Ziyi Jin, et al.. (2018). Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. Clinical Therapeutics. 40(2). 309–319. 13 indexed citations

Nader, Ahmed, Akshanth R. Polepally, Mohan Liu, et al.. (2018). Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical Pharmacokinetics. 57(10). 1295–1306. 23 indexed citations

Lin, Chih‐Wei, Nael M. Mostafa, Dennis L. Andress, et al.. (2017). Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy. Clinical Therapeutics. 40(2). 242–251. 16 indexed citations

Ng, Juki, et al.. (2017). Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women. The Journal of Clinical Endocrinology & Metabolism. 102(5). 1683–1691. 81 indexed citations

Noertersheuser, Peter, Rajendra Pradhan, Cheri E. Klein, et al.. (2011). Exposure—Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis. The Journal of Clinical Pharmacology. 52(8). 1162–1173.

Ng, Juki, et al.. (2011). Pharmacokinetics and Safety of the Lopinavir/Ritonavir Tablet 500/125 mg Twice Daily Coadministered With Efavirenz in Healthy Adult Participants. The Journal of Clinical Pharmacology. 52(8). 1248–1254. 3 indexed citations

10.

Campo, Rafael, Barbara A. da Silva, Laurent Cotte, et al.. (2009). Predictors of Loss of Virologic Response in Subjects Who Simplified to Lopinavir/Ritonavir Monotherapy from Lopinavir/Ritonavir Plus Zidovudine/Lamivudine. AIDS Research and Human Retroviruses. 25(3). 269–275. 14 indexed citations

11.

Klein, Cheri E., Yi‐Lin Chiu, Kathryn R. King, et al.. (2008). Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir. The Journal of Clinical Pharmacology. 48(5). 553–562. 36 indexed citations

12.

Chiu, Yi‐Lin, Cheri E. Klein, William C. Woodward, et al.. (2007). Lack of Effect of Gastric Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir in HIV-Infected Patients. AIDS Patient Care and STDs. 21(4). 247–251. 10 indexed citations

13.

Klein, Cheri E., Yi‐Lin Chiu, Walid M. Awni, et al.. (2007). The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect. JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(4). 401–410. 117 indexed citations

14.

Kempf, Dale J., Cheri E. Klein, Hui-Ju Chen, et al.. (2007). Pharmacokinetic Enhancement of the Hepatitis C Virus Protease Inhibitors VX-950 and SCH 503034 by Co-Dosing with Ritonavir. Antiviral chemistry & chemotherapy. 18(3). 163–167. 33 indexed citations

15.

Podzamczer, Daniel, Martin King, Cheri E. Klein, et al.. (2007). High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response. HIV Clinical Trials. 8(4). 193–204. 14 indexed citations

16.

Cameron, D. William, Stephen Becker, Martin King, et al.. (2007). Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Journal of Antimicrobial Chemotherapy. 59(5). 957–963. 14 indexed citations

17.

Yeh, Rosa F., Kristine B. Patterson, Naser L. Rezk, et al.. (2006). Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes. 42(1). 52–60. 159 indexed citations

18.

Klein, Cheri E., Helen Kastrissios, Antonius A. Miller, et al.. (2005). Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemotherapy and Pharmacology. 57(2). 199–206. 23 indexed citations

19.

Adjei, Alex A., Cheri E. Klein, Helen Kastrissios, et al.. (2000). Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity. Journal of Clinical Oncology. 18(5). 1116–1116. 52 indexed citations

20.

Avram, Michael J., Tom C. Krejcie, Claus U. Niemann, et al.. (1997). The Effect of Halothane on the Recirculatory Pharmacokinetics of Physiologic Markers . Anesthesiology. 87(6). 1381–1393. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact